Doxorubicin for Dogs: Uses in Chemotherapy & Side Effects

See your vet immediately if your dog has trouble breathing, collapses, develops a fever, has repeated vomiting or diarrhea after chemotherapy, or seems suddenly weak. Dogs receiving doxorubicin can become sick quickly if white blood cell counts drop or if heart complications develop.

This article is educational only. Doxorubicin is a prescription chemotherapy drug that must be given by trained veterinary professionals through a carefully monitored IV infusion. Your vet or veterinary oncologist will decide whether it fits your dog’s cancer type, stage, heart health, bloodwork, and quality-of-life goals.

Never try to give doxorubicin at home, and never use leftover chemotherapy drugs from another pet. If your dog is actively receiving chemotherapy, ask your vet for written instructions about home monitoring, waste handling, and what symptoms should trigger an urgent recheck.

Doxorubicin is one of the most widely used injectable chemotherapy drugs in veterinary oncology. It belongs to the anthracycline family and works in several ways, including damaging cancer-cell DNA and interfering with enzymes cancer cells need to divide. Because it targets rapidly dividing cells, it can also affect normal tissues like the intestinal lining and bone marrow.

In dogs, doxorubicin is given only as a slow intravenous infusion at a veterinary hospital or specialty oncology center. Merck Veterinary Manual lists it as an important antineoplastic drug for lymphoma, osteosarcoma, hemangiosarcoma, and other sarcomas and carcinomas, and notes that it should be infused over about 15 to 30 minutes. VCA also notes that chemotherapy side effects in dogs often involve the GI tract and bone marrow because those tissues turn over quickly.

Doxorubicin is not a take-home medication. It requires careful catheter placement and trained handling because leakage outside the vein can cause severe local tissue injury. Your vet may recommend it as a single drug or as one part of a larger chemotherapy plan, depending on your dog’s diagnosis and goals of care.

Doxorubicin is best known for its role in canine lymphoma treatment. It is one of the drugs used in CHOP-based protocols, which remain a common standard option for many dogs with high-grade multicentric lymphoma. In that setting, the goal is usually remission and good quality of life rather than cure.

Veterinary oncologists also use doxorubicin for several other cancers. Merck Veterinary Manual includes lymphoma, leukemias, multiple myeloma, osteosarcoma, hemangiosarcoma, and a range of sarcomas and carcinomas among its recognized indications. In practice, that often means doxorubicin may be used after surgery for splenic hemangiosarcoma, after local treatment for osteosarcoma, or in selected soft tissue and epithelial cancers.

Whether doxorubicin makes sense depends on the tumor type, stage, spread, prior treatments, and your dog’s heart function. Some dogs are better candidates for multi-drug chemotherapy, while others may do better with a single-agent plan, palliative treatment, or supportive care only. Your vet can help match the treatment intensity to your dog’s medical needs and your family’s goals.

Doxorubicin is usually dosed by body surface area, not by body weight alone. In many protocols it is given every 2 to 3 weeks, but the exact schedule varies with the cancer being treated, whether it is being combined with other drugs, and how your dog tolerated earlier doses.

Before treatment, your vet will usually check a complete blood count and may also recommend chemistry testing and heart screening. Merck notes that doxorubicin should not be used in dogs with impaired left ventricular function because of its known cardiotoxicity. Dogs with pre-existing heart disease, large cumulative exposure, or breed-related cardiac risk may need closer monitoring.

There is also a practical lifetime limit to how much doxorubicin a dog can safely receive because heart damage is cumulative. That is why many dogs receive a finite number of doses over a defined protocol rather than staying on the drug indefinitely. If blood counts, GI side effects, or heart findings become concerning, your vet may delay treatment, reduce the dose, switch drugs, or stop doxorubicin altogether.

The most common short-term side effects are stomach and intestinal upset and bone marrow suppression. VCA notes that vomiting and diarrhea often appear about 3 to 5 days after chemotherapy, while low blood cell counts are monitored with follow-up bloodwork. Merck specifically lists nausea, vomiting, moderate myelosuppression, hemorrhagic colitis, transient ECG changes or arrhythmias, and severe tissue injury if extravasation occurs.

The most important long-term risk is cumulative heart muscle damage. Merck identifies doxorubicin as a cause of dose-related cardiomyopathy in dogs, and also states it should not be used in dogs with impaired left ventricular function. This risk is why some dogs need baseline or repeat echocardiography, especially if they already have a murmur, a known heart condition, or are approaching higher cumulative exposure.

Some dogs also become tired, eat less, or run a fever if white blood cell counts drop enough to allow infection. Hair loss is usually mild in most breeds, but dogs with continuously growing coats, such as Poodles and Old English Sheepdogs, may lose more hair than short-coated breeds. Red or orange urine can occur after treatment and is usually drug pigment rather than blood, but your vet should still be told about any urinary changes.

Call your vet promptly if your dog has repeated vomiting, severe diarrhea, bloody stool, poor appetite lasting more than a day, fever, shaking, collapse, trouble breathing, or marked weakness. Those signs do not always mean a serious complication, but they deserve fast guidance.

Doxorubicin is commonly combined with other chemotherapy drugs, so interaction planning is part of routine oncology care. The main concern is not a single over-the-counter interaction, but the way multiple cancer drugs can add up in terms of bone marrow suppression, GI effects, and organ stress. Your vet will time treatments and bloodwork to reduce those risks.

Heart health matters too. Merck advises against using doxorubicin in dogs with impaired left ventricular function, and that caution becomes even more important if a dog is receiving other medications that may affect the heart. Some oncology teams also use dexrazoxane in selected cases to help reduce tissue injury from accidental extravasation or to address cardiotoxicity concerns, although protocols vary.

PetMD notes that dogs with an ABCB1, also called MDR1, mutation may handle some chemotherapy drugs differently, including doxorubicin. That does not automatically rule the drug out, but it can affect monitoring and dose planning. Tell your vet about every medication, supplement, and herbal product your dog receives, including heart medications, NSAIDs, appetite aids, and anti-nausea drugs.

Most dogs can keep eating their usual complete diet during doxorubicin treatment, but appetite may dip for a few days after each infusion.

Doxorubicin is not breed-specific, but the cancers it treats are more common in some breeds than others. Coat type also matters. Dogs with continuously growing hair are more likely to show visible coat thinning or hair loss during chemotherapy, while many short-coated dogs show little to none.

undefined: undefined

undefined: undefined

undefined: undefined

undefined: undefined